These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 3494428

  • 1. [Adoptive immunotherapy of cancer patients with lymphokine-activated killer cells].
    Taguchi T, Domoto K.
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):914-21. PubMed ID: 3494428
    [Abstract] [Full Text] [Related]

  • 2. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
    Schoof DD, Gramolini BA, Davidson DL, Massaro AF, Wilson RE, Eberlein TJ.
    Cancer Res; 1988 Sep 01; 48(17):5007-10. PubMed ID: 3261630
    [Abstract] [Full Text] [Related]

  • 3. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ, Yang J, Shu S, Rosenberg SA.
    J Immunol; 1986 May 15; 136(10):3899-909. PubMed ID: 2871106
    [Abstract] [Full Text] [Related]

  • 4. [LAK cells and cancer].
    Taguchi T, Kimoto Y.
    Gan To Kagaku Ryoho; 1986 Dec 15; 13(12):3327-33. PubMed ID: 3539024
    [Abstract] [Full Text] [Related]

  • 5. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA, Belinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, Roberts JD, Albertini RJ, Branda RF.
    Cancer Res; 1990 Oct 01; 50(19):6302-10. PubMed ID: 2205379
    [Abstract] [Full Text] [Related]

  • 6. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R, Rosenberg SA.
    J Immunol; 1985 Dec 01; 135(6):4273-80. PubMed ID: 3877766
    [Abstract] [Full Text] [Related]

  • 7. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
    Rosenberg SA, Mulé JJ.
    Surgery; 1985 Sep 01; 98(3):437-44. PubMed ID: 3898451
    [Abstract] [Full Text] [Related]

  • 8. [Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas].
    Yoshida S, Takai N, Ono K, Saito T, Tanaka R.
    No To Shinkei; 1988 Feb 01; 40(2):119-25. PubMed ID: 3259433
    [Abstract] [Full Text] [Related]

  • 9. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH, Mills BJ, Gemlo BT, Holden H, Mier J, Paietta E, McMannis JD, Escobedo LV, Sniecinski I, Rayner AA.
    Cancer Res; 1988 Aug 01; 48(15):4409-16. PubMed ID: 3260537
    [Abstract] [Full Text] [Related]

  • 10. [Clinical studies of adoptive immunotherapy of human disseminated brain tumors with LAK cells and recombinant interleukin-2].
    Okamoto Y, Shimizu K, Miyao Y, Yamada M, Ushio Y, Matsui Y, Hayakawa T, Tago H, Ikeda H.
    No To Shinkei; 1986 Jun 01; 38(6):593-8. PubMed ID: 3488068
    [Abstract] [Full Text] [Related]

  • 11. [Effectiveness of treatment with transfer of autologous or allogenic LAK cells combined with rIL-2 in 121 patients with malignant pleural effusion].
    Liu X.
    Zhonghua Zhong Liu Za Zhi; 1993 May 01; 15(3):205-8. PubMed ID: 8261867
    [Abstract] [Full Text] [Related]

  • 12. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
    Lafreniere R, Rosenberg SA.
    Cancer Res; 1985 Aug 01; 45(8):3735-41. PubMed ID: 3893689
    [Abstract] [Full Text] [Related]

  • 13. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y.
    Hokkaido Igaku Zasshi; 1992 Jul 01; 67(4):475-87. PubMed ID: 1330859
    [Abstract] [Full Text] [Related]

  • 14. [Intrapleural transfer of LAK cells combined with rIL-2 in the treatment of advanced lung cancer with malignant pleural effusion].
    Li DJ.
    Zhonghua Zhong Liu Za Zhi; 1989 Jul 01; 11(4):294-6. PubMed ID: 2625114
    [Abstract] [Full Text] [Related]

  • 15. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.
    Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT.
    N Engl J Med; 1985 Dec 05; 313(23):1485-92. PubMed ID: 3903508
    [Abstract] [Full Text] [Related]

  • 16. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
    Mulé JJ, Shu S, Rosenberg SA.
    J Immunol; 1985 Jul 05; 135(1):646-52. PubMed ID: 3889158
    [Abstract] [Full Text] [Related]

  • 17. [Adoptive immunotherapy of malignant diseases with LAK cells].
    Kimoto Y, Tanji Y, Tanaka T, Taguchi T.
    Gan To Kagaku Ryoho; 1987 Mar 05; 14(3 Pt 1):687-92. PubMed ID: 3493732
    [Abstract] [Full Text] [Related]

  • 18. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
    Vujanovic NL, Herberman RB, Hiserodt JC.
    Cancer Res; 1988 Feb 15; 48(4):878-83. PubMed ID: 3257411
    [Abstract] [Full Text] [Related]

  • 19. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ, Ettinghausen SE, Spiess PJ, Shu S, Rosenberg SA.
    Cancer Res; 1986 Feb 15; 46(2):676-83. PubMed ID: 3484431
    [Abstract] [Full Text] [Related]

  • 20. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N, Ozaki A, Ishihara J, Sakurai M, Sasaki Y, Takahashi H, Sano T, Hoshi A.
    Gan To Kagaku Ryoho; 1986 Apr 15; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.